By: IPP Bureau
Last updated : December 26, 2023 8:02 pm
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Astellas Pharma has completed the acquisition of Propella Therapeutics that has become a wholly owned subsidiary of Astellas.
Through the acquisition of Propella, Astellas has acquired PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer. PRL-02 is a novel, long-acting prodrug of abiraterone that, following intramuscular injection, is expected to achieve high concentrations in target tissues where the active moiety, abiraterone, is continuously released.
PRL-02 may provide improved efficacy and safety compared to existing treatment options by high CYP17 lyase inhibition selectivity. PRL-02 is currently in a Phase 1 clinical trial and is expected to enter Phase 2a clinical trials in 2024.
Under the agreement, Astellas paid approximately US $175 million to acquire all of the outstanding common stock and equity interests in Propella.
The impact of this transaction on Astellas' financial results in the fiscal year ending March 31, 2024, will be limited.